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Abstract: Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a 
third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in 
reducing the risk of fractures in patients with postmenopausal osteoporosis and recent   low-trauma 
hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between 
Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction 
of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma 
hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated 
and very convenient, it is an interesting therapeutic option for aging patients who take multiple 
oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication 
for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. 
Vitamin D deficiency should be corrected before the administration of Zol.
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Introduction
Burden of the disease
According to World Health Organization (WHO) data, osteoporosis affects 
approximately 75 million people throughout Europe, the US, and Japan.1 In the US, 
osteoporosis occurs in 55% of the population aged 50 years and over.2 Osteoporosis 
occurs more in women than in men. One in four women over the age of 50 years has 
osteoporosis in Canada.3 Increasing life expectancy means that the prevalence of the 
disease is likely to increase. It is estimated that, for example, in Canada, by 2041, 25% 
of the population will be aged 65 years and over.4
Definition of osteoporosis
Osteoporosis is a skeletal disease that is characterized by compromised bone strength 
predisposing a person to an increased risk of fracture.5 Bone strength is a combination 
of bone density and bone quality. Overall bone strength is difficult to measure in the 
clinical setting. In the absence of fragility fracture, bone mineral density (BMD), a proxy 
measure that accounts for up to 70% of bone strength, is the clinical tool used to diagnose 
osteoporosis according to the classification of the WHO. BMD that is 2.5   standard 
deviations or more below the mean BMD of a young adult reference population, 
which is a T-score of -2.5 or less, qualifies for a diagnosis of osteoporosis.6 As BMD 
decreases, fracture risk increases.7 Fractures associated with osteoporosis are a major 
cause of morbidity, disability, mortality, and costs.8 Mortality rate is increased by 20% 
in the year following a hip fracture.9 Furthermore, 50% of women who   suffer from a Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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hip fracture will not return to their usual level of   functioning 
and will depend on others for their daily activities; 20% of 
them will require long-term care.9   Therefore, it is crucial to 
prevent osteoporosis and fractures.
Risk factors of low BMD
For patients without fragility fracture, BMD is clearly a good 
predictor of future fracture risk, and therefore it is important 
to identify who should be evaluated by BMD. Risk factors 
for osteoporosis have been identified and are summarized 
in Table 1.10 Every postmenopausal woman and every male 
aged 50 years and over should be assessed for the presence 
of risk factors for low BMD (Table 1). A BMD measurement 
is recommended when at least one risk factor is identified in 
each age category.11
Risk factors of fractures
Low BMD is an important risk factor for fractures, but many 
other epidemiological risk factors have been identified and 
included in a WHO model of 10-year fracture risk predic-
tion, the FRAX® model (World Health Organization Col-
laborating Centre for Metabolic Bone Diseases, Sheffield, 
UK).12 This model is based on individual patient models that 
integrate clinical risk factors as well as BMD at the femoral 
neck. The FRAX model has been developed from studying 
population-based cohorts from Europe, North America, Asia, 
and Australia.
According to Osteoporosis Canada, an individual’s 
10-year absolute fracture risk can also be identified by 
  integrating five key risk factors for fractures: gender, age, 
BMD, fragility fracture history, and glucocorticoid use.13
Strategies in prevention and management 
of osteoporosis
Prevention of osteoporosis or low BMD is preferable to 
treatment because bone microarchitectural changes are 
mostly irreversible. Strategies for osteoporosis prevention 
include maximizing peak bone mass during the bone   forming 
years and should favour good nutrition, physical activity, 
avoidance of cigarette smoking and excess alcohol intake, and 
minimized administration of drugs known to alter bone health 
(eg,   glucocorticoids, anticonvulsivants). Once the peak bone 
mass is achieved, strategies to minimize bone loss should also 
be included. In the US, the Food and Drug Administration 
(FDA) distinguishes between drugs approved for prevention 
of osteoporosis and those for treatment.14 For prevention 
of osteoporosis, the FDA suggests that in future studies the 
study population should consist of ambulatory women who 
are 1–2 years postmenopausal, aged 45 years or older, and 
do not have osteoporosis, or ovariectomized women with 
elevated follicle-stimulating hormone and low estradiol lev-
els. In the aging osteoporotic population with and without 
fragility fracture, it is too late for maximizing peak bone mass 
and preventing osteoporosis. Therefore, stabilizing BMD or 
reducing the rate of bone loss is the   primary objective. In the 
case of patients with fragility fracture, there is established 
osteoporosis, so secondary fracture prevention should be the 
main objective. This review will focus on strategies used in 
i) postmenopausal women, ii) women and men with recent 
low-trauma hip fracture, and iii) glucocorticoid-treated patients 
to prevent bone loss and fractures. Strategies used in idiopathic 
male osteoporosis and in men on androgen   deprivation therapy 
(ADT) will also be reviewed briefly. Among the therapeutic 
agents available for the prevention of fractures and treatment 
of osteoporosis, bisphosphonates are the most commonly used 
drugs. Less than 1% of oral bisphosphonates are absorbed 
orally. Therefore, oral bisphosphonates must be taken on an 
empty stomach, and patients should remain fasting for at least 
30 minutes in order to maximize their absorption.15 So oral 
bisphosphonates have to be taken when getting up in morning 
and, in addition, patients should not lie down after their intake, 
in order to avoid oesophageal irritation. These constraints have 
Table 1 Indications for measuring bone mineral density
Age ,50 years Age 50–64 years Age $65 years
Fragility fracture Fragility fracture after age 40 years All men and women
Prolonged use of glucocorticoids Prolonged use of glucocorticoids or other high-risk medications
Use of high-risk medications Parental hip fracture
Hypogonadism or premature menopause (age ,45 years) Vertebral fracture or osteopenia identified on radiography
Malabsorption syndrome High alcohol intake or current smoking
Chronic inflammatory conditions Low body weight (,60 kg) or major weight loss  
(.10% of body weight at age 25 years)
Primary hyperparathyroidism Other disorders strongly associated with  
osteoporosis
Other disorders strongly associated with rapid bone  
loss and/or fracture
Adapted from Papaioannou A, Morin S, Cheung AM, et al. © 2010. CMAJ.10 This work is protected by copyright and the making of this copy was with the permission of Access 
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raised adherence issues. Poor   adherence to oral   bisphosphonates 
has been shown to be   associated with suboptimal fracture 
reduction and prevention.16,17 Weekly and monthly oral or 
intravenous (IV)   bisphosphonate regimens have been devel-
oped and approved to address this issue. A single infusion of IV 
  zoledronic acid (Zol) (Reclast®, Aclasta®; Novartis Pharmaceu-
ticals   Corporation, East Hanover, NJ, USA), a third-generation 
bisphosphonate, has been conceived to allow better tolerance 
and better adherence to bisphosphonate therapy.
Zoledronic acid
Clinical pharmacology
Mechanism of action
Zol is a member of the nitrogen-containing   bisphosphonates 
class and acts on bone in a potent way to decrease osteoclast-
mediated bone resorption.18 Like other bisphosphonates, 
Zol has a high affinity for mineralized bone and binds to 
the calcium phosphate bone mineral hydroxyapatite,19 with 
  preferential localization at sites of high bone turnover. 
In vitro, when compared with alendronate, ibandronate, 
risedronate, etidronate, and clodronate, Zol has the highest 
affinity for hydroxyapatite.19 Several independent studies 
have confirmed that an enzyme of the mevalonate pathway 
of lipid biosynthesis (farnesyl pyrophosphate synthase 
[FPP]) is the major enzymatic target of Zol. Zol inhibits FPP, 
which is critical for the regulation of various cell processes 
that are important for osteoclast function.20   Inhibition of 
such an enzyme could be responsible for inhibition of 
osteoclast-mediated bone resorption, as well as osteoclast 
apoptosis.21 According to in vitro studies, Zol appears to 
inhibit FPP 3-, 7-, 17-, and 67-fold more effectively than 
risedronate, ibandronate, alendronate, and pamidronate, 
respectively.20
Pharmacokinetic profile
Distribution
There are currently no pharmacokinetic data available for 
patients with postmenopausal osteoporosis (PMO) or recent 
low-trauma hip fracture. Data in this section are from studies 
in patients with bone metastases in whom single and/or 
multiple IV infusions of Zol of 5 or 15 minutes’ duration 
were administered.22 However, as administration of single-
dose Zol is recommended in patients with PMO, this section 
focuses on a single-dose pharmacokinetic profile. Peak Zol 
plasma concentrations (Cmax) are reached at the end of the 
infusion period, after which the Zol concentration decreases 
rapidly, reaching concentrations to ,1% of Cmax 24 hours 
postinfusion. The drug is 43%–55% plasma protein bound 
independent of concentration.23
Metabolism and excretion
Zol is not metabolized in humans; it is excreted intact via 
the kidney. An average of 39% of the administered Zol is 
excreted in the urine within the first 24 hours.23 The rest 
of the dose is presumed to be bound to bone and released 
back into the circulation very slowly. The clearance of Zol 
is dependent on creatinine clearance (CrCL). However, no 
significant change in exposure to Zol was noted in patients 
with mild (50–80 mL/min) to moderate renal impairment 
(35–50 mL/min) compared with patients with normal renal 
function.24 Dosage is not adjusted for mild or moderate renal 
failure, but Zol is not recommended in patients with severe 
renal impairment (,35 mL/min) because of the lack of data 
in this population.23 No effect has been shown on cytochrome 
P450. The pharmacokinetics of Zol were not affected by 
gender, race, or age in patients who ranged in age from 38 
to 84 years.23
Pharmacodynamic effects
Zol reduces rapidly the rate of bone turnover, first by reduc-
ing the resorption and then the formation. Biochemical 
markers of bone resorption were more suppressed by Zol 
compared with placebo25 and alendronate26 in women with 
PMO25 or low BMD26 in studies of 24 weeks’26 or 3 years’25 
duration. In patients with PMO, the effect of Zol treatment 
on markers of bone resorption (serum β-C-telopeptides 
[β-CTx]) and bone formation (bone specific alkaline phos-
phatase [BSAP], serum N-terminal propeptide of type 1 
collagen [P1NP]) was evaluated in patients at periodic 
intervals. Treatment with a 5 mg annual dose of Zol reduced 
bone turnover   markers to the premenopausal range with an 
approximate 55% reduction in β-CTx, a 29% reduction in 
BSAP, and a 52%   reduction in P1NP over 36 months. There 
was no progressive   reduction of bone turnover markers 
with repeated annual dosing.25 Zol produced more marked 
and rapid decrease in markers than oral alendronate 70 mg 
once weekly in patients with osteoporosis or low BMD.26 
The nadir of each resorption marker was reached at 7 days 
and for formation markers at 12 weeks.26 Subgroup analyses 
of the main trial of Zol in PMO,25 HORIZON-PFT (Health 
Outcomes and Reduced Incidence with Zoledronic Acid Once 
Yearly – Pivotal Fracture Trial), revealed that the changes 
in bone markers in patients treated with Zol versus placebo 
were not influenced by age.27,28
Efficacy
Postmenopausal women
The efficacy of Zol was demonstrated in   HORIZON-PFT for 
the treatment of osteoporosis in postmenopausal   women.25 Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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HORIZON-PFT  was  a  randomized,  double-blind, 
  placebo-controlled, multinational study of 7736 women 
aged 65–89 years. The majority of patients were 70–74 years 
old (38% in both groups). Inclusion criteria were either a 
femoral neck BMD T-score #-1.5 and at least two mild or 
one moderate existing vertebral fracture(s), or a femoral neck 
BMD T-score #-2.5 with or without evidence of an existing 
vertebral fracture(s). The trial excluded patients previously 
treated with strontium, parathyroid hormone, or sodium 
fluoride. Zol, as a single 5 mg infusion over 15 minutes, was 
administered yearly for 3 consecutive years.
Fractures
In HORIZON-PFT, the two primary efficacy endpoints were 
the incidence of morphometric vertebral fractures at 3 years 
and the incidence of hip fractures over a median duration of 
3 years. Patients were divided into two strata (stratum 1 and 2). 
In stratum 1, 6084 women were not receiving concomitant 
osteoporosis therapy at baseline. In stratum 2, 1652 patients were 
receiving antiosteoporosis therapy at baseline.   Concomitant 
therapy included   calcitonin, raloxifene, tamoxifen, hormone 
replacement therapy,   dehydroepiandrosterone, ipriflavone, 
medroxyprogesterone, and tibolone but excluded bisphos-
phonates. All women received 1000–1500 mg of calcium plus 
400–1200 IU of vitamin D each day.
As shown in Table 2, IV Zol 5 mg once yearly   significantly 
reduced the risk of new morphometric vertebral fracture 
by 70% (absolute reduction in fracture incidence 7.6% 
over 3 years when compared with placebo in patients in 
stratum 1). Significant reduction in the relative risk (RR) of 
new vertebral fracture was seen as soon as 1 year (relative 
risk reduction [RRR] = 60%) and after 2 years of treatment 
(RRR = 71%).
IV Zol also significantly reduced the risk of new hip 
  fractures by 41% at 3 years compared with placebo in the 
overall patient population (stratum 1 and 2) (Table 2). The hip 
fracture event rate was 1.45% for Zol-treated patients and 
2.5% for placebo-treated patients. According to the monograph, 
the reductions in vertebral and hip fractures over 3 years 
were consistent and significantly reduced independent of 
age, number of vertebral fractures at baseline, geographical 
region, race, baseline body mass index, femoral neck BMD 
T-score, or prior use of bisphosphonates. Specifically, in 
patients aged 75 years and older, Zol-treated patients had a 
60% decrease in RRR for vertebral fractures compared with 
placebo patients (P , 0.0001). IV Zol 5 mg once yearly was 
also effective in reducing the risk of all secondary endpoints 
such as clinical vertebral fractures (RRR of 77%), any 
clinical fracture (RRR of 33%), and nonvertebral fracture 
(RRR of 25%) in the overall patient population (  stratum 1 
and 2) during the 3-year treatment period (Table 2). The 
risk of   multiple morphometric vertebral fractures was 
also   significantly reduced by 89% when compared with 
placebo (0.2% vs 2.3% of patients) in patients without any 
  concomitant osteoporosis treatment (stratum 1).
BMD
In HORIZON-PFT, the secondary efficacy measure 
included the percentage change from baseline in lumbar 
spine, femoral neck, and total hip BMD.29 Zol significantly 
Table 2 effects of zoledronic acid on incident fractures
Study Endpoint Absolute reduction  
in fracture incidence %  
(95% CI)
Relative risk reduction  
in fracture incidence %  
(95% CI)
P value
Postmenopausal women  
(HORIZON-PFT)
Vertebral fracture
Over 12 months 2.2 60 (43–72) ,0.0001
Over 24 months 5.5 71 (62–78) ,0.0001
Over 36 months 7.6 70 (62–76) ,0.0001
Hip fracture
Over 36 months 1.1 41 (17–58) P = 0.0024
Nonvertebral fractures
Over 36 months 2.7 25 (13–36) ,0.0001
Patients with hip fracture  
(HORIZON-RFT)
Any clinical fracture 5.3 35 (16–50) 0.001
Clinical vertebral fracture 2.1 46 (8–68) 0.02
Nonvertebral fracture 3.1 27 (2–45) 0.03
Hip fracture 1.5 30 (19–59) 0.18Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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increased BMD at the lumbar spine, total hip, and femoral 
neck compared with placebo at 6, 12, 24, and 36 months 
(Table 3).
Histology, remodeling markers, and bone strength
The effect of Zol on bone histology was also evaluated.25,29 
Biopsies taken in patients after 3 years of Zol had   significantly 
lower median activation frequency,   mineralizing surfaces, 
and bone formation rate (volume referent) than biopsies from 
patients in the placebo group. Even if bone turnover was sup-
pressed, bone remodeling was still present in all but one of 
82 iliac crest biopsies and in all 70 biopsies of the placebo 
recipients.30 Bone quality did not appear to be impaired in 
PMO patients in the Zol group. No   evidence of woven bone, 
marrow fibrosis, or cellular toxicity was demonstrated in bone 
biopsies from these patients.30 In HORIZON-PFT, annual 
injections of Zol reduced   remodeling markers in the premeno-
pausal range, with a significant response   persisting after the 
third   infusion.27 Zol was also effective in improving some 
indices of bone strength in PMO in the   HORIZON-PFT, as 
  measured by quantitative computed tomography scan.31 After 
3 years, Zol patients had   significantly increased compression 
strength indices at the femoral neck and   trochanter, and simi-
lar   bending strength indices at the   femoral neck compared 
with   placebo. Improvement in cortical bone was also dem-
onstrated in the Zol group.31 In another study looking at the 
biopsies obtained during HORIZON, the authors used Raman 
microspectroscopy (a vibrational spectroscopic   technique 
that analyzes undecalcified bone tissue) to determine the 
effect of Zol on bone material properties, such as the mineral/
matrix ratio at similar tissue age. This study suggests that 
once-yearly administration of IV Zol for 3 years in humans 
exerts effects on bone matrix formation quality, in addition 
to the known antiresorptive effects and independently of 
bone turnover.32
Postmenopausal women with low  
bone mass
Zol has also been approved for the prevention of PMO 
during a 2-year period. In this 2-year double-blind, random-
ized, multicenter, clinical study (n = 581), three treatment 
arms were compared: group 1, Zol 5 mg IV at randomization 
and at month 12 (Zol 2 × 5 mg); group 2, Zol 5 mg IV only 
at randomization and placebo at month 12 (Zol 1 × 5 mg); 
or group 3, placebo at randomization and at month 12 
(  placebo). Both Zol regimens (groups 1 and 2) signifi-
cantly increased mean lumbar spine BMD compared with 
placebo (group 3) at month 12 and 24. Similarly, greater 
increases in hip BMD were observed at month 12 and 24 in 
groups 1 and 2 compared with those in group 3. Both Zol 
regimens significantly reduced bone markers. The yearly 
Zol (group 1, ie, Zol 2 × 5 mg) administration suppressed 
the bone markers in a more sustained way during the   second 
year than the single dose regimen (group 2, ie, Zol 1 × 5 mg). 
Therefore, the recommended prophylactic regimen of Zol 
is a single dose of 5 mg every 2 years administered IV 
during a period of 15 minutes. Daily supplementation with 
elemental calcium 500–1000 mg plus 400–800 IU vitamin 
D is recommended.33
In a double-blind, randomized, placebo-controlled trial 
over 2 years, 50 postmenopausal women with low bone mass 
were randomized to Zol 5 mg × 1 versus placebo. Compared 
with placebo, Zol decreased levels of remodeling markers 
by 38% for 2 years; after 2 years, BMD was higher in the 
Zol group than in the placebo group (+5.7% at lumbar spine, 
3.9% at proximal femur, and 1.7% at the total body).34
Patients with hip fracture  
(men and women)
The clinical efficacy of Zol in patients with a recent low-
trauma hip fracture was investigated in a large randomized, 
double-blind, placebo-controlled,   multicenter 5-year study, 
  HORIZON-Recurrent Fracture Trial (RFT).35
Fractures
In HORIZON-RFT, 2127 men and women aged $50 years 
with low-trauma hip fracture were randomly assigned 
to receive yearly Zol (5 mg) (n = 1065) or placebo 
(n = 1062) within 3 months of surgical repair.35 Exclu-
sion criteria included previous treatment with strontium 
or sodium   fluoride, a metabolic disease of the bone other 
than   osteoporosis, cancer, a ClCr , 30 mL/min, a serum 
  calcium level of .2.8 or ,2.0 mmol/L, or a life expectancy 
of ,6 months. A washout period was included for patients 
Table 3 effects of zoledronic acid on bone mineral density (BMD)
Study Location BMD change relative  
to treatment with  
placebo
P value
HORIZON-PFT  
at 36 months
Lumbar spine +6.7% ,0.0001
Femoral neck +5.1% ,0.0001
Total hip +6.0% ,0.0001
HORIZON-RFT  
over 24 months
Total hip +5.4% ,0.001
Femoral neck +4.3% ,0.001
Abbreviation: BMD bone mineral density.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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who had   previously received bisphosphonates or parathyroid 
hormone.35 Subjects also received vitamin D (50,000–125,000 
IU) 14 days prior to infusion, if 25(OH) vitamin D was 
,15 ng/dL or unknown, and 800 to 1200 IU daily thereafter 
and calcium. Concomitant treatment with selective estrogen 
receptor modulators, nasal calcitonin, tibolone, hormone 
replacement therapy, and external hip protectors was allowed. 
After a median follow-up of 1.9 years, new clinical fractures 
occurred in 8.6% and 13.9% of patients in the Zol and placebo 
groups, representing a significant decrease in RRR of 35% 
(Table 2). There was also a 46% RRR in clinical vertebral 
fracture and a 27% RRR in nonvertebral fractures (Table 2). 
The RR for a subsequent hip fracture was reduced by 30%, 
but this did not reach statistical significance, most likely due 
to the small number of cases.
BMD
As shown in Table 3, Zol 5 mg resulted in significant increases 
in BMD for the total hip and femoral neck (5.4% at the total 
hip and 4.3% at the femoral) over 24 months as compared 
with placebo) in males and females analyzed together. In the 
male subgroup, a greater increase was demonstrated in total 
hip BMD at month 24 with Zol (3.81%; P = 0.0021) versus 
placebo, suggesting a comparable effect in both genders.36 
This trend continued to be observed at 36 months.
Glucocorticoid-induced osteoporosis
The efficacy and safety of Zol in the   glucocorticoid-induced 
osteoporosis (GIO) trial were assessed in a   randomized, 
  multicenter, double-blind, stratified (treatment and preven-
tion), active-controlled study of 833, mainly Caucasian, men 
and women aged 18–85 years treated with .7.5 mg/day oral 
prednisone or equivalent.37 The prevention group was com-
posed of patients who were treated with glucocorticoids for 
less than 3 months prior to   randomization. Patients in the treat-
ment group were treated with glucocortiocids for 3 months 
or more. Patients were randomized either to Zol 5 mg or oral 
risedronate. It was a noninferiority trial. All patients were on 
elemental calcium 1000 mg plus vitamin D 400–1000 IU per 
day. Results showed that Zol was   noninferior and superior to 
risedronate for increase of lumbar spine BMD in the treatment 
(+4.06% vs 2.71%) and prevention groups (2.6% vs 0.64%) 
after 12 months. At the lumbar spine, the increase in BMD 
was statistically significant for postmenopausal women and 
men but not for premenopausal women. Concentrations of 
biomarkers for bone resorption and formation were reduced 
by both drugs but more importantly at 12 months for patients 
on Zol than for patients on risedronate in both the   prevention 
and treatment groups. The frequency of new vertebral 
fractures was very low in Zol and risedronate patients with 
no significant difference between the two groups.37
In males
Idiopathic osteoporosis
A recent study by Orwoll et al compared the efficacy and 
safety of a once-yearly IV infusion of Zol with weekly oral 
alendronate in men with osteoporosis.38 This study was a mul-
ticenter, randomized, double-blind, double-dummy, active-
controlled efficacy trial in a male only study of 302 men 
with osteoporosis aged 25–86 years (mean age 64 years) 
in which patients were randomized for 2 years to either Zol 
5 mg once yearly or to oral alendronate 70 mg weekly. All 
participants received 1000 mg calcium plus 800–1000 IU 
vitamin D supplementation per day. The Zol infusion was 
shown to be noninferior to weekly alendronate for the per-
centage change in lumbar spine BMD at month 24 relative 
to baseline (Zol 6.1% vs alendronate 6.2%). The differences 
in BMD increases at lumbar spine, total hip, femoral neck, 
and trochanter at month 6, 12, or 24 were not statistically 
significant between Zol and alendronate.
On androgen deprivation therapy (ADT)
ADT for prostate cancer is associated with accelerated bone 
loss and increased fracture risk.39 Zol 4 mg IV every 3 months 
for four treatments has been demonstrated to prevent bone 
loss in patients initiating ADT40 and to improve BMD in 
patients with prostate cancer (without metastasis) on ADT 
for 1 year or less or for greater than 1 year.41 It is important to 
note that no data exist on the effect of Zol 5 mg once yearly 
in such population.
Safety
Hypocalcemia
In HORIZON-PFT, between 9 and 10 days following the 
infusion, hypocalcemia (serum calcium ,2.075 mmol/L) 
was reported in 1.27% of Zol recipients versus 0.03% of 
placebo recipients.25 In HORIZON-RFT, the incidence of 
hypocalcemia was also low (0.3% in the Zol group vs 0% 
in the placebo group).35 It is recommended that all patients 
should have their serum calcium levels and vitamin D levels 
assessed before initiating the treatment with Zol. Pre-existing 
hypocalcemia is a contraindication to Zol and should be 
  corrected before the infusion with calcium and vitamin D. 
In addition, sufficient vitamin D supplementation to ensure 
and maintain adequate serum 25(OH) vitamin D levels should 
be given before and after Zol infusion.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Atypical subtrochanteric fractures
Recent case series have suggested the possibility that low-
trauma subtrochanteric hip fractures may be increased in 
long-term users of bisphosphonates.42–48 Although the optimal 
duration of bisphosphonate use for osteoporosis is unknown, 
these atypical fractures may be related to long-term bisphos-
phonate use. The FDA issued a Drug Safety Communication 
in October 2010 and will require a new Limitations of Use 
statement in the Indications and Usage section of the labels 
for these drugs. This statement will describe the uncertainty 
of the optimal duration of use of bisphosphonates for the 
treatment and/or prevention of osteoporosis.49
As compared with placebo, the relative hazard of atypical 
subtrochanteric fracture was 1.50 (95% confidence interval 
0.25–9.00, ie, nonsignificant) for Zol use in   HORIZON-PFT.25 
After 3 years of treatment, Zol did not seem to be associated 
with an increased risk of atypical subtrochanteric fractures.50 
However, this outcome is very rare and is very difficult to 
assess in a single clinical trial.
Osteonecrosis of the jaw
Over recent years, cases of osteonecrosis of the jaw (ONJ) 
have emerged in patients receiving bisphosphonates. 
In the majority of cases, patients with ONJ were patients 
with multiple myeloma or metastatic breast cancer treated 
with IV Zol or pamidronate.51 There has been no case of 
  spontaneous reports of ONJ in either HORIZON trials.25,35 
In   HORIZON-PFT, blinded adjudication/expert review of 
adverse events identified one Zol and one placebo   recipient 
with symptoms compatible with ONJ (according to the 
adjudication committee definition: exposed bone in the 
maxillofacial area with delayed healing for more than 6 weeks 
despite appropriate care).52 However, long-term studies are 
needed in this area. ONJ has been reported rarely in the 
treatment of PMO with Zol as well as with other oral and 
IV bisphosphonates.51,53 The majority of the cases have been 
reported where there had been dental   procedures. A   routine 
dental examination is recommended prior to treatment. 
Patients with associated risk factors (  cancer, chemotherapy, 
glucocorticoids, dental procedure, poor oral hygiene) should 
have preventive dentistry prior to the infusion. While on treat-
ment, these patients should avoid major dental procedures.
Cardiovascular adverse events
In HORIZON-PFT, arrhythmia occurred significantly more 
often in the Zol recipients than in the placebo recipients 
(6.9% vs 5.3%, P = 0.003).25 Serious atrial fibrillation   (needing 
hospital admission) occurred more often in the   Zol-treated 
patients than in those receiving the placebo (1.3% vs 0.5%, 
P , 0.001).25 Among the 50 patients who developed atrial 
fibrillation in the Zol group, the events occurred more than 
30 days after infusion in 47 patients (94%). This increased 
incidence has not been confirmed in HORIZON-RFT, the 
Paget trial,54 nor the trial for   prevention of PMO.33,55 In addi-
tion, the incidence of any atrial fibrillation was   similar 
between the Zol recipients and the placebo recipients in 
each of the HORIZON trials.25,35 No mechanism has been 
found to explain this increased   incidence of atrial   fibrillation. 
Osteoporosis and atrial   fibrillation are diseases that are more 
common in the elderly and that share some risk factors. 
After reviewing all the clinical studies involving the various 
bisphosphonates, the FDA issued a statement in November 
2008 that “Across all studies, no clear association between 
overall   bisphosphonate exposure and the rate of serious or 
non-serious atrial   fibrillation was observed”.49
Renal failure
Once-yearly Zol was not associated with long-term renal 
toxicity in patients with PMO25 or a recent low-trauma hip 
fracture.35 After 3 years of treatment, in HORIZON-PFT, 
Zol and placebo recipients did not differ with regard to 
mean changes in CrCL, creatinine levels, incidence of renal 
abnormalities, or estimated $30% reduction in CrCL.56 The 
renal tolerability of Zol was also similar to that of placebo 
in HORIZON-RFT.35 However, it is important to note that 
Zol is contraindicated in patients with severe renal impair-
ment. Moreover, Zol appeared more effective in preventing 
vertebral fractures in women with normal renal function.1 It 
is of utmost importance that the duration of infusion should 
not be shorter than 15 minutes, as more rapid infusions have 
been associated with impairment of renal function in the 
oncology setting, where other risk factors such as pre-existing 
renal disease and concomitant use of nephrotoxic drugs can 
contribute.57–59 In addition, patients should be well hydrated 
before the infusion.
Geriatrics
HORIZON-PFT and -RFT when taken together included 
4761 Zol-treated patients aged 65 years and older and 2083 
patients aged 75 years and older. No difference was noted in 
safety or efficacy according to age.25 However, in a subgroup 
analysis that was preplanned and post hoc, a greater Zol 
protective effect for vertebral fracture was seen in women 
of younger age.1
In the osteoporosis study in men cited in the mono-
graph, 38.3% (n = 59) of Zol-treated patients were 65 years Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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and older and 15.6% (n = 24) were 75 years and older.23 
No difference was noted in safety or efficacy according to 
age neither in this study nor in the GIO trial,37 where 27.9% 
of Zol-treated patients were 65 years and older and 7% were 
75 years and older.
Ocular adverse events
Patients who were treated with Zol had an absolute increase 
of 0.69% (3.34% vs 2.65%) in inflammatory ocular adverse 
events (mainly conjunctivitis) in the first 15 days after 
the infusion.25 In HORIZON-RFT, only one case of iritis 
was reported in the Zol group.35 In the male osteoporosis 
trial, two cases of conjunctivitis and one case of eye pain 
were reported in the Zol group and one case of iritis in 
the   alendronate group.23,60 In the GIO trial, one case of 
  conjunctivitis was reported in the Zol group.37
Tolerability
Zol 5 mg administered via a 15-minute IV infusion was 
generally well tolerated in patients with PMO,25,29 low BMD,29 
male idiopathic osteoporosis,61 GIO,37 or recent low-trauma 
hip fracture.35 All bisphosphonates, including Zol, have a risk 
of rare occurrence of severe and sometimes incapacitating 
pain in the bones, joints, and muscles. This risk of muscu-
loskeletal symptoms has been highlighted by the FDA. The 
FDA suggests that bisphosphonates should be discontinued 
if such symptoms appear.49
Adverse reactions
versus placebo
The most common adverse events that occurred statistically 
more in Zol than in placebo patients were athralgias (23.8% 
vs 20.4%), pyrexia (17.9% vs 3.7%), flu-like symptoms 
(8.8% vs 2.7%), nausea (8.5% vs 5.2%), bone pain (5.8% vs 
2.3%), and chills (5.4% vs 1%) in HORIZON-PFT.25 Many 
of these symptoms were reported in the 3 days following the 
infusion and occurred significantly more in the Zol group 
than in the placebo recipients. In HORIZON-RFT, patients 
received paracetamol at the time of infusion and after the 
infusion. In this study, only pyrexia and myalgia occurred 
significantly more in the Zol group than in the placebo group 
but at a lower rate (8.7% vs 3.1%).37 The symptoms usually 
resolved within 3 days.
versus alendronate or risedronate
The percentage of patients experiencing adverse events is 
comparable in patients receiving Zol (single dose) and oral 
alendronate or risedronate once weekly, with the exception 
of a higher incidence of postinfusion symptoms in the 3 days 
following the infusion.37,61
Follow-up
Calcium
It is suggested that all patients should have a calcium and 
vitamin D level measured before treatment with Zol. In the 
PMO trial, patients received 1000–1500 mg of elemental 
calcium plus 400–1200 IU of vitamin D.25 In the trial on 
the prevention of fractures in patients who suffered a recent 
low-trauma hip fracture, subjects also received   vitamin D 
(50,000–125,000 IU) 14 days prior to infusion if 25(OH) 
vitamin D was ,15 ng/dL or unknown and 800–1200 IU 
daily thereafter and calcium.35
Renal function
Given that bisphosphonates are not recommended for patients 
with CrCL , 30, a measure of creatinine is recommended 
before each infusion. Renal toxicity has been reported with 
some IV bisphosphonates, including Zol. This situation was 
mainly observed in cancer patients when the duration of the 
infusion was shorter than 15 minutes.59 Patients should be 
well hydrated prior to the infusion.
Patient satisfaction and quality of life
Once-yearly IV administration of bisphosphonate appears to 
be preferred over once-weekly oral administration, according 
to data from the 1-year study in patients with PMO or low 
BMD previously treated with alendronate.29 In this study, 
78.7% patients preferred a once-yearly IV regimen, 9% 
preferred a once-weekly oral regimen, and 11.8% considered 
both treatment regimens to be comparable.
Compliance to osteoporosis treatment regimens is poor 
in general.62 The fact that Zol is administered once yearly 
in a 15-minute infusion could help with regard to patient 
adherence to therapy compared with other bisphosphonates 
or other osteoporosis treatments. With the Zol treatment 
regimen, the medication is completely absorbed, and its 
efficacy at protecting the patient against fracture lasts for 
1 year.
Place of zoledronic acid in the treatment 
and prevention of osteoporosis
The management of skeletal health in the elderly should 
be focused toward minimizing bone loss and   prevention 
of fractures. All patients should receive lifestyle   education 
(physical activity, avoidance of cigarettes and alcohol) and 
nonpharmacological therapy (adequate calcium intake, Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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  vitamin D) in order to preserve BMD and strength.2 
For elderly patients with low bone mass, GIO, or   osteoporosis 
who are at increased risk of fractures,   bisphosphonates 
are first-line therapy (for women and men). However, for 
  raloxifene, other   considerations such as risk of   cancer, 
venous   thromboembolism, and hot flashes must be 
  considered (Table 4). If bisphosphonates are   indicated, Zol 
should be considered an alternative for patients who cannot 
tolerate oral bisphosphonates, patients with significant 
  gastroesophageal reflux or peptic ulcer disease, and patients 
with Barrett’s esophagus or who have difficulty with dosing 
  requirements (such as remaining fasting and sitting upright 
for 30–60 minutes and/or swallowing a pill). Compared with 
other bisphosphonates, Zol has the highest affinity for bone 
Table 4 Comparison of different agents used in the treatment of postmenopausal osteoporosis, GIO, or male osteoporosis
Drug Route of administration Adverse effects Contraindications Indications
Bisphosphonates Severe renal failure,  
hypocalcemia,  
hypersensitivity,  
pregnancy
PMO, GIO, MO
Zoledronic acid Iv infusion once yearly Transient postinfusion  
influenza-like illness,  
concerns about  
arrhythmia and serious  
atrial fibrillation, mild  
transient hypocalcemia
Ibandronate Iv injection 3 monthly Transient postinjection  
influenza-like illness
No hip fracture protection   
for oral ibandronate
Alendronate Oral once monthly Caution in patients with  
GeRD or peptic ulcer  
disease
Oral tablet once daily;  
once weekly
Contraindication in Barrett’s  
esophagus and inability to sit  
upright for 30–60 minutes
Risedronate Oral tablet once daily,  
once weekly, once twice  
weekly, once monthly
Selective estrogen receptor modulators
Raloxifene Oral tablet once daily Hot flashes and leg  
cramps, concerns  
about vTe
vTe past or present,  
liver failure, moderate  
or severe renal failure,  
patients with coronary  
heart disease: increased  
risk of stroke or death
PMO, no hip fracture  
protection
Anabolic agents
PTH (1–34, 1–84) Subcutaneous injection  
once daily
Severe renal or liver  
impairment, metabolic  
bone disease, previous  
radiation therapy involving  
the skeleton, hypercalcemia,  
elevation of ALP, bone  
metastases, skeletal  
malignancies
PMO, GIO, MO
Others
Strontium Oral suspension  
once daily
Severe hypersensitivity  
syndromes have been  
described and vTe, diarrhea
Severe renal failure,  
past vTe?
Calcitonin Intranasal PMO, GIO, MO
Monoclonal antibody  
against RANKL
Denosumab Subcutaneous injections  
once every 6 months
Concerns about immune  
system (skin infection,  
diverticulitis, pneumonia,  
appendicitis)
PMO, GIO, MO
Abbreviations: ALP, alkaline phosphatase; GERD, gastroesophageal reflux disease; GIO, glucocorticoid-induced osteoporosis; IV, intravenous; MO, male osteoporosis; 
PMO, postmenopausal osteoporosis; PTH, parathyroid hormone; RANKL, receptor activator of nuclear factor kappa-B ligand; vTe, venous thromboembolism.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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mineral and is the most potent inhibitor of FPP. Adherence to 
osteoporosis regimens is poor. Because Zol is administered 
once yearly in a clinical setting, it may help patients with 
compliance. Further clinical experience is needed to confirm 
that these characteristics can have an impact on fracture 
protection. Special attention should be given to vitamin D 
deficiency treatment before the infusion. Bisphosphonates 
and Zol, in particular, are generally not recommended for 
patients with CrCL , 35 mL/min. Currently, there is no 
consensus with regard to the duration of bisphosphonate 
treatment.
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